TET3 Antibody

Product Specifications

Background

TET3 Antibody: TET3, a member of the ten-eleven-translocation (TET) family of genes, is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine and is most abundantly expressed in hematopoietic cells. Unlike the related TET2 protein, mutations in TET3 have not been observed in any myeloid malignancies. TET3 has been shown to be involved in the demethylation of zygotic DNA before the first mitosis and has been suggested to be involved in the epigenetic reprogramming of the zygotic paternal DNA following natural fertilization and may also contribute to somatic cell nuclear reprogramming during animal cloning.

NCBI Gene ID

200424

Swiss Prot

O43151

Accession Number

NP_001274420

Host

Rabbit

Reactivity

Human, Mouse, Rat

Clonality

Polyclonal

Conjugation

Unconjugated

Type

Primary Antibodies

Field of Research

Stem Cell

Purification

TET3 Antibody is affinity chromatography purified via peptide column.

Positive Control

Cat. No. 1220 - SK-N-SH Cell Lysate

Concentration

1 mg/mL

Buffer

TET3 Antibody is supplied in PBS containing 0.02% sodium azide.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

TET3 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Calculated Molecular Weight

183 kDa

Fragment

IgG

Specificity

At least three isoforms of TET3 are known to exist. TET3 antibody is predicted to not cross react with other TET proteins.

Symbol

TET3

Positive Control 2

Cat. No. 10-301 - Human Brain Tissue Slide

NCBI Official Name

TET methylcytosine dioxygenase 3

NCBI Organism

Homo sapiens

Background Reference 01

Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat. Genet. 2009; 41:838-42.

Background Reference 02

Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2011; 115:2003-7.